Drug development

Certara to Acquire Pinnacle 21, a Leader in Data Standardization Software for Pharmaceutical Clinical Data

Company, Chief executive officer, Statistics, Efficiency, Pinnacle, Clinical trial, Webcast, Forward-looking statement, Phrase, Earnings before interest, taxes, depreciation and amortization, Community, Organization, Technology, Adoption, Machine learning, Jefferies Group, Software, Clinical Data Interchange Standards Consortium, Growth, Patient, US Foods, Drug discovery, Medicines and Healthcare products Regulatory Agency, Food and Drug Administration, Risk, PMDA, Simpson Thacher & Bartlett, Nasdaq, Drug development, R, Compliance, National Music Publishers' Association, Conference, Doctor of Philosophy, Private Securities Litigation Reform Act, Acquisition, GLOBE, Medical device, Pharmaceutical industry
Thursday, August 5, 2021 - 9:15pm

Pinnacle 21 is a leader in biopharmaceutical data fitness, which streamlines quantitative analyses needed by our clients.

Key Points: 
  • Pinnacle 21 is a leader in biopharmaceutical data fitness, which streamlines quantitative analyses needed by our clients.
  • The acquisition will immediately establish Certara as a central participant in the data standardization process across the entire drug development life cycle.
  • Certara is the ideal partner for Pinnacle 21s exceptional team and customer base, said Max Kanevsky, Founder and CEO of Pinnacle 21.
  • Pinnacle 21 is a global leader in software for preparing clinical trial data for regulatory submission.

Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

MD, AbbVie, Research, Sumathi Best Television Current Reporting Award, Industry, U.S. Securities and Exchange Commission, VBR, HBeAg, Annual report, Hepatitis C, Nobel Prize, Securities Act of 1933, Therapy, Virology, Patient, COVID-19, Board, Securities Exchange Act of 1934, European Association for the Study of the Liver, AO, Hepatitis, SEC, Assembly, SAN, ATM, Doctor of Philosophy, Drug development, Safety, Board of directors, Conference, Acquisition, Hepatitis B virus, HBV, GLOBE, Pharmaceutical industry, Medical device, Animal
Thursday, August 5, 2021 - 9:01pm

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent highlights for the second quarter ended June 30, 2021.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent highlights for the second quarter ended June 30, 2021.
  • Announced the promotions of Jason Okazaki to chief operating officer and Michael Samar to chief financial officer.
  • Presented data from Assembly Bios three clinical-stage core inhibitor programs, vebicorvir (VBR or ABI-H0731), ABI-H2158 (2158), and ABI-H3733 (3733), in an oral presentation and two poster presentations at EASL 2021.
  • More information about Assembly Bios risks and uncertainties are more fully detailed under the heading Risk Factors in Assembly Bios filings with theSEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Oncternal Provides Business Update and Announces Second Quarter 2021 Financial Results

California Institute for Regenerative Medicine, Clinical trial, Woman, Chief executive officer, UC, Webcast, U.S. Securities and Exchange Commission, Forward-looking statement, Senior, Orr, CLL, Progression-free survival, Asco, Corporate development, Breast cancer, MCL, PFS, Private Securities Litigation Reform Act, Regenerative medicine, Venetoclax, Cancer, Rule, Patient, CRS, CIRM, GLOBE, ROR1, Mantle cell lymphoma, ETS, University of California, San Diego, Hematological Cancer Research Investment and Education Act, Paclitaxel, OS, Risk, Chronic lymphocytic leukemia, Aplastic anemia, Nasdaq, Research, Drug development, BTK, Therapy, Ewing's sarcoma, California, CR, Disease, Pharmaceutical industry, Communications satellite
Thursday, August 5, 2021 - 9:01pm

ET

Key Points: 
  • ET
    SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today reported financial results for the second quarter of 2021.
  • ET to provide a business update and discuss its second quarter of 2021 financial results.
  • Our grant revenue was $0.9 million for the second quarter ended June 30, 2021.
  • Our total operating expenses for the second quarter ended June 30, 2021 were $8.6 million, including $1.8 million in non-cash stock based compensation.

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results

Chief executive officer, Clinical trial, Association, U.S. Securities and Exchange Commission, Investment, Forward-looking statement, R, Institute of Liver and Biliary Sciences, Master of Business Administration, Liver disease, Private Securities Litigation Reform Act, Drug, European Association for the Study of the Liver, HBsAg, CTA, Viral hepatitis, ASO, HVS, Therapy, Patient, Growth, COVID-19, Degenerative disease, Cam, Data, CHB, Phase 1, HBS, Nash, RNA, Fatty liver disease, Nasdaq, Doctor of Philosophy, Exercise, ILC, Research, Drug development, Terminology, Sirna, Hepatitis, Security (finance), GLOBE, Pharmaceutical industry, Fine chemical
Thursday, August 5, 2021 - 9:05pm

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the second quarter, June 30, 2021.

Key Points: 
  • STOPS and CAM programs: initial data presented at conferences, dosing in 2nd CHB cohorts ongoing
    SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the second quarter, June 30, 2021.
  • At recent scientific conferences, healthy volunteer data from our STOPSprogram and initial antiviral data in CHB subjects from our CAM program, were presented.
  • For both the STOPS and CAM programs, enrollment in the first CHB cohort is complete and is ongoing in the second cohort.
  • Data from additional cohorts are expected to be presented at one or more scientific conferences in the second half of 2021.

Quanterix Corporation Releases Operating Results for Second Quarter of 2021

Science, Cardiology, Other Science, Biotechnology, Pharmaceutical, Oncology, Health, Infectious Diseases, AFL, Plasma, Corporation, Neurodegeneration, Webcast, Policy, Blood, Neuro, Biomarker, Industry, Diagnosis, Science, Publication, Lists of diseases, Goldman, Nature Communications, Food and Drug Administration, ID, Drug development, Biotechnology, Chief financial officer, Conference, GAAP, Nasdaq, PerkinElmer, Cryptocurrency, Medical imaging, Mobile phone, Pharmaceutical industry, Management
Thursday, August 5, 2021 - 9:18pm

Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three months ending June 30, 2021.

Key Points: 
  • Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three months ending June 30, 2021.
  • Record Product Revenue of $18.7M for Q2 2021, an increase of 175% versus prior year Q2.
  • Quanterix Simoa technology was highlighted in 130 new publications, bringing total Simoa-specific inclusions to more than 1,300 publications.
  • In conjunction with this announcement, Quanterix Corporation will host a conference call on August 5 at 4:30pm EDT.

Yossi Borenstein, CEO and Founder of Shizim Group, has been Elected to the Can-Fite Board

Health, Medical Devices, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Transfer, Company, Chief executive officer, International Life Sciences Institute, Founder, Communications and Information Technology Commission (Saudi Arabia), U.S. Securities and Exchange Commission, United, Industry, Tel Aviv Stock Exchange, Psoriasis, Technology, Hepatocellular carcinoma, Fatty liver disease, Melanoma, Writing, Cuban American National Foundation, Risk, General manager, Bristol Myers Squibb, Digital health, Cancer, Erectile dysfunction, Patient, COVID-19, Hong Kong International Medical Devices and Supplies Fair, The Co Founder, SEC, Liver cancer, Nash, New York Stock Exchange, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Prostate, HCC, Robotics, Drug development, Liver, Colon, Food, Nasdaq, Forward-looking statement, Pharmaceutical industry
Thursday, August 5, 2021 - 2:18pm

During the past 35 years, Mr. Yossi Bornstein has played key roles in the Israeli biomed industry.

Key Points: 
  • During the past 35 years, Mr. Yossi Bornstein has played key roles in the Israeli biomed industry.
  • Mr. Bornstein is the CEO and the founder of Shizim group, a life science holding company.
  • Mr. Bornstein is the founder of ILSI - Israel Life Science Industry Organization and Founder of ITTN - Israel Tech Transfer Organization.
  • We welcome Yossi Borenstein as an External Director and trust that his skills will be highly valuable for Can-Fite, stated Can-Fite CEO Pnina Fishman.

Ultivue Announces Co-Marketing Agreement with Fluidigm for Biomarker Imaging Solutions for Precision Medicine

Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Chief executive officer, Efficiency, Research, Solution, Business development, Workflow, Technology, Government, Fluidigm, Health, Microfluidics, Biomarker, Quality of life, Cancer, Triage, Precision medicine, Immunotherapy, CyTOF, Drug development, Business, Biotechnology, Disease, Pharmaceutical industry, Medical imaging
Thursday, August 5, 2021 - 2:30pm

Ultivue , a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation develops unique assays for use in multiplex immunofluorescence imaging and analysis.

Key Points: 
  • Ultivue , a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation develops unique assays for use in multiplex immunofluorescence imaging and analysis.
  • Fluidigm is a leader in high-parameter imaging for the clinical translational research and clinical testing markets.
  • Through Fluidigm Therapeutic Insights Services, we will offer our customers access to our technology as well as that of Ultivue, providing optimum imaging solutions for biomarker discovery and drug development.
  • Fluidigm, the Fluidigm logo, and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries.

Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results

Company, Head and neck cancer, U.S. Securities and Exchange Commission, Forward-looking statement, American Association, Asco, Drug resistance, American Society of Clinical Oncology, Patent, Pancreatic cancer, Administration, Programmed cell death protein 1, Annual report, Private Securities Litigation Reform Act, AACR, Large-cell lung carcinoma, Insurance, CEACAM1, Patient, COVID-19, Celecoxib, GLOBE, Cetuximab, Legislation, Society, STAT3, Bristol Myers Squibb, Cancer, Intention, SEC, General officer, Food and Drug Administration, Hypertension, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Survival, Drug development, IRS2, SG, ESOP, CM postcode area, Annual general meeting, American Association for Cancer Research, Safety, Head, Nivolumab, Marketing, Food, Neck, Pharmaceutical industry, Cryptocurrency, Animal
Thursday, August 5, 2021 - 1:30pm

REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (Purple Biotech, or the Company) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today provided a corporate update and announced financial results for the six months ended June 30, 2021.

Key Points: 
  • REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (Purple Biotech, or the Company) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today provided a corporate update and announced financial results for the six months ended June 30, 2021.
  • We achieved significant progress in the advancement of our promising oncology pipeline during the first half of 2021, said Isaac Israel, Chief Executive Officer of Purple Biotech.
  • Initial results from the first dose level cohort showed that NT219 was well-tolerated with minimal serious adverse events.
  • These are factors that we believe could cause our actual results to differ materially from expected results.

Fluidigm Announces Co-Marketing Agreement with Ultivue for Biomarker Imaging Solutions for Precision Medicine

H&E stain, Efficiency, Research, Chief executive officer, U.S. Securities and Exchange Commission, Solution, Forward-looking statement, United, Industry, Life, Corporate development, Technology, Coronavirus, Data analysis, Annual report, Government, Private Securities Litigation Reform Act, Regulation, Security (finance), Mass cytometry, TIS, Health, Twitter, Microfluidics, Biomarker, GLOBE, Quality of life, Mass, Cancer, Regulation Fair Disclosure, SAN, Triage, Precision medicine, Social media, Immunotherapy, CyTOF, Drug development, Biotechnology, Disclosure, LinkedIn, Acquisition, Nasdaq, Disease, Pharmaceutical industry, Medical imaging, Risk management
Thursday, August 5, 2021 - 1:30pm

Ultivue , a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique assays for use in multiplex immunofluorescence imaging and analysis.

Key Points: 
  • Ultivue , a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique assays for use in multiplex immunofluorescence imaging and analysis.
  • For example, InSituPlex technology is well-suited to identify regions of interest that may require downstream, deep profiling with Imaging Mass Cytometry.
  • Ultivue is at the forefront of innovation to provide unique biological insights for our customers, said Mark Rees, Vice President of Corporate Development for Ultivue.
  • Through Fluidigm Therapeutic Insights Services, we will offer our customers access to our technology as well as that of Ultivue, providing optimum imaging solutions for biomarker discovery and drug development.

Fluidigm Announces Collaboration Agreement with Imaging CRO ImaBiotech to Increase Biopharma Access to Imaging Mass Cytometry

Chief executive officer, Research, Trinidad and Tobago Securities and Exchange Commission, Forward-looking statement, United, Industry, Good laboratory practice, Life, Technology, Adoption, Coronavirus, GLP, Annual report, Government, Private Securities Litigation Reform Act, Regulation, Nasdaq, Security (finance), Partnership, Health, Twitter, Microfluidics, Biomarker, GLOBE, Toxicity, Quality of life, Cancer, Mass spectrometry imaging, Regulation Fair Disclosure, SAN, Precision medicine, Immunotherapy, Histology, Social media, CyTOF, Doctor of Philosophy, Drug development, Biotechnology, Disclosure, Environment, LinkedIn, Acquisition, CRO, Disease, Pharmaceutical industry, Medical imaging, Fine chemical
Thursday, August 5, 2021 - 1:35pm

Our customers expressed a need for high-multiplex imaging, and that compelled us to acquire a Hyperion Imaging System to meet market needs.

Key Points: 
  • Our customers expressed a need for high-multiplex imaging, and that compelled us to acquire a Hyperion Imaging System to meet market needs.
  • We are excited for the opportunity to collaborate with Fluidigm in this regard, innovating applications and products, including new panel development, to make Imaging Mass Cytometry an even more powerful tool.
  • Mass cytometry technologies, including CyTOF , Imaging Mass Cytometry and Maxpar Direct, have been used in more than 160 clinical trials, including 10 utilizing IMC.
  • Fluidigm, theFluidigmlogo, CyTOF, Direct, Hyperion, Imaging Mass Cytometry, IMC, and Maxpar, are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries.